Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Subscribe To Our Newsletter & Stay Updated
